【摘要】：目的:探討DC-CIK細(xì)胞治療腎透明細(xì)胞癌臨床療效及治療次數(shù)對患者預(yù)后的影響。方法:回顧性分析2004年1月至2011年6月在福建省腫瘤醫(yī)院診療的100例腎透明細(xì)胞癌患者,其中63例在福建省腫瘤生物治療重點實驗室進(jìn)行自體DC-CIK細(xì)胞免疫治療聯(lián)合常規(guī)治療為DC-CIK細(xì)胞治療組,其余37例未經(jīng)DC-CIK細(xì)胞治療為對照組,比較兩組患者的5年DFS和OS。治療組按照DC-CIK細(xì)胞治療療程數(shù)分成≤3個療程組及3個療程組,分析DC-CIK細(xì)胞治療療程數(shù)對腎透明細(xì)胞癌患者5年DFS和OS的相關(guān)性。結(jié)果:DC-CIK細(xì)胞治療組患者5年OS較對照組明顯提高(81.05%vs 60.29%,P0.05),但5年DFS無顯著性差異(P0.05);DC-CIK細(xì)胞治療療程數(shù)3個的患者5年OS較對照組明顯提高(P0.05),但5年DFS無顯著性差異(P0.05)。結(jié)論:自體DC-CIK細(xì)胞回輸聯(lián)合常規(guī)治療手段治療腎透明細(xì)胞癌更有生存優(yōu)勢,且DC-CIK細(xì)胞治療療程數(shù)與腎透明細(xì)胞癌患者的預(yù)后密切相關(guān)。
[Abstract]:Objective: to investigate the clinical efficacy of DC-CIK cells in the treatment of renal clear cell carcinoma (RCC) and the effect of the times of treatment on the prognosis of the patients. Methods: 100 patients with renal clear cell carcinoma diagnosed and treated in Fujian Cancer Hospital from January 2004 to June 2011 were retrospectively analyzed. Among them, 63 cases were treated with autologous DC-CIK cell immunotherapy combined with routine therapy in Fujian Provincial key Laboratory of Cancer Biotherapy, and the other 37 cases were treated without DC-CIK cells as control group. Comparison of 5-year DFS and OS. between the two groups The patients in the treatment group were divided into 鈮，

本文編號：2456506